---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-022329"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:54:47.451962+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Absci Q2 net loss $28.7M, exceeds Active Program guidance, restructures to extend cash to late-2025

## Summary
- Net loss of $28.7M in Q2 2022, compared to $41.2M loss in Q2 2021.
- Cash and equivalents $206.0M as of June 30, 2022, down from $252.6M at Dec 31, 2021; 2022 cash decrease expected ~$110M.
- Signed ten new Active Programs year-to-date, exceeding full-year guidance of at least eight; total now 19.
- Strategic reorganization reduces headcount and extends cash runway into late 2025; workforce reduction included.
- Entered multi-program collaboration with undisclosed biotech for antibody-drug conjugates using Bionic technology.

## SEC filing metadata
- accession: 0001628280-22-022329
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828022022329/0001628280-22-022329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828022022329/absc-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-022329
- JSON: https://secwatch.observer/filing/0001628280-22-022329.json
- Plain text: https://secwatch.observer/filing/0001628280-22-022329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.